Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of MK-3222 versus placebo and etanercept in moderate-to-severe chronic plaque psoriasis
NL-OMON50707Phase 3Active, not recruiting
- Sponsor
- Sun Pharma
- Start
- Dec 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tildrakizumab in psoriasis and plaque psoriasis (4 arms), sponsored by Sun Pharma. Primary endpoints: PASI 75 at Week 12, PGA clear or minimal at Week 12 and 2 more. Started Dec 2013; status: active, not recruiting.
02
Drugs
tildrakizumab
03
Conditions
psoriasisplaque psoriasis
Beyond the preview
Go deeper on NL-OMON50707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50707.